ANNX (Annexon, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ANNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Mark S. Blumenkranz | Director | A | — | — |
| 2026-06-15 | Muneer A Satter | Director | A | — | — |
| 2026-06-15 | WILLIAM A JONES JR | Director | A | — | — |
| 2026-06-15 | Bettina M. Cockroft | Director | A | — | — |
| 2026-06-15 | William H. Carson | Director | A | — | — |
| 2026-06-15 | Jung Choi | Director | A | — | — |
| 2026-06-15 | William D. Waddill | Director | A | — | — |
| 2026-06-15 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | M | — | — |
| 2026-05-29 | Muneer A Satter | Director | Buy | — | — |
| 2026-05-13 | William H. Carson | Director | Buy | — | — |
| 2026-04-14 | William H. Carson | Director | Buy | — | — |
| 2026-03-12 | William H. Carson | Director | Buy | — | — |
| 2026-03-04 | DEAN RICHARD ARTIS | EVP & CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-03-04 | Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | Sell | — | — |
| 2026-03-04 | Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-03-04 | Jamie Dananberg | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-03-04 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | Sell | — | — |
| 2026-02-23 | Jamie Dananberg | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-02-23 | Douglas Love | PRESIDENT AND CEO | A | — | — |
| 2026-02-23 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | A | — | — |
| 2026-02-23 | Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | A | — | — |
| 2026-02-23 | DEAN RICHARD ARTIS | EVP & CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2026-02-23 | Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-02-20 | Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | Sell | — | — |
| 2026-02-20 | Jamie Dananberg | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2026-02-20 | Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-02-20 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | Sell | — | — |
| 2026-02-20 | DEAN RICHARD ARTIS | EVP & CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2026-01-02 | William H. Carson | Director | Buy | — | — |
| 2025-12-03 | Jung Choi | Director | Buy | — | — |
| 2025-12-03 | William H. Carson | Director | Buy | — | — |
| 2025-11-21 | Muneer A Satter | Director | Buy | — | — |
| 2025-11-19 | Muneer A Satter | Director | Buy | — | — |
| 2025-10-31 | William H. Carson | Director | Buy | — | — |
| 2025-10-02 | William H. Carson | Director | Buy | — | — |
| 2025-09-04 | William H. Carson | Director | Buy | — | — |
| 2025-08-01 | William H. Carson | Director | Buy | — | — |
| 2025-07-16 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | Sell | — | — |
| 2025-07-16 | Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-07-16 | Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | Sell | — | — |
| 2025-07-01 | William H. Carson | Director | Buy | — | — |
| 2025-06-09 | William H. Carson | Director | A | — | — |
| 2025-06-09 | WILLIAM A JONES JR | Director | A | — | — |
| 2025-06-09 | Bettina M. Cockroft | Director | A | — | — |
| 2025-06-09 | Muneer A Satter | Director | A | — | — |
| 2025-06-09 | William D. Waddill | Director | A | — | — |
| 2025-06-09 | Jung Choi | Director | A | — | — |
| 2025-06-09 | THOMAS G WIGGANS | Director | A | — | — |
| 2025-03-03 | Douglas Love | PRESIDENT AND CEO | A | — | — |
| 2025-03-03 | Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 10,342,134 | — |
| — | 10%+ Owner | 5,701,926 | — |
| — | 10%+ Owner | 2,841,628 | — |
| — | 10%+ Owner | 2,730,635 | — |
| — | 10%+ Owner | 1,596,222 | — |
| — | 10%+ Owner | 808,914 | — |
| — | PRESIDENT AND CEO | 351,554 | — |
| — | EVP & CHIEF INNOVATION OFFICER | 184,807 | — |
| — | EVP & CHIEF BUSINESS OFFICER | 182,625 | — |
| — | EVP & CHIEF SCIENTIFIC OFFICER | 180,093 | — |
| — | EVP & CHIEF FINANCIAL OFFICER | 170,700 | — |
| — | CHIEF MEDICAL OFFICER | 123,582 | — |
| — | Director | 78,405 | — |
| — | Director | 33,000 | — |
| — | EVP & Chief Scientific Officer | 17,188 | — |
| — | EVP & Chief Medical Officer | 12,500 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANNX quote page; the site-wide leaderboard is on the insider transactions hub.